(2015) Stepwise high-throughput virtual screening of Rho kinase inhibitors from natural product library and potential therapeutics for pulmonary hypertension, Pharmaceutical Biology, 53:8, 1201-1206, DOI: 10.3109/13880209.2014
ORIGINAL ARTICLEStepwise high-throughput virtual screening of Rho kinase inhibitors from natural product library and potential therapeutics for pulmonary hypertension Hao Su, Ji Yan, Jian Xu, Xi-Zhen Fan, Xian-Lin Sun, and Kang-Yu Chen Department of Cardiology, Anhui Provincial Hospital, Hefei, China Abstract Context: Pulmonary hypertension (PH) is a devastating disease characterized by progressive elevation of pulmonary arterial pressure and vascular resistance due to pulmonary vasoconstriction and vessel remodeling. The activation of RhoA/Rho-kinase (ROCK) pathway plays a central role in the pathologic progression of PH and thus the Rho kinase, an essential effector of the ROCK pathway, is considered as a potential therapeutic target to attenuate PH. Objective: In the current study, a synthetic pipeline is used to discover new potent Rho inhibitors from various natural products. Materials and methods: In the pipeline, the stepwise high-throughput virtual screening, quantitative structure-activity relationship (QSAR)-based rescoring, and kinase assay were integrated. The screening was performed against a structurally diverse, drug-like natural product library, from which six identified compounds were tested to determine their inhibitory potencies agonist Rho by using a standard kinase assay protocol. Results: With this scheme, we successfully identified two potent Rho inhibitors, namely phloretin and baicalein, with activity values of IC 50 ¼ 0.22 and 0.95 mM, respectively. Discussion and conclusion: Structural examination suggested that complicated networks of nonbonded interactions such as hydrogen bonding, hydrophobic forces, and van der Waals contacts across the complex interfaces of Rho kinase are formed with the screened compounds.